关键信息
-
基因名
CBFA2T3
- 应用
-
别名
Cbfa2t3; Ccore binding factor runt domain alpha subunit 2 translocated to 3; ETO2; hMTG16; hMTG16a; hMTG16b; MTG16; MTG16_HUMAN; MTG8 related gene 2
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75081
-
表达区间
1-615aa
-
氨基酸序列
MPASRLRDRAASSASGSTCGSMSQTHPVLESGLLASAGCSAPRGPRKGGPAPVDRKAKASAMPDSPAEVKTQPRSTPPSMPPPPPAASQGATRPPSFTPHTLMNGSSHSPTAINGAPCTPNGFSNGPATSSTASLSTQHLPPACGARQLSKLKRFLTTLQQFGSDISPEIGERVRTLVLGLVNSTLTIEEFHSKLQEATNFPLRPFVIPFLKANLPLLQRELLHCARLAKQTPAQYLAQHEQLLLDASASSPIDSSELLLEVNENGKRRTPDRTKENGSDRDPLHPQRYSPSNGPPQPTPPPHYRLEDIAMAHHFRDAYRHPDPRELRERHRPLVVPGSRQEEVIDHKLTEREWAEEWKHLNNLLNCIMDMVEKTRRSLTVLRRCQEADREELNHWARRYSDAEDTKKGPAPAAARPRSSSAGPEGPQLDVPREFLPRTLTGYVPEDIWRKAEEAVNEVKRQAMSELQKAVSDAERKAHELITTERAKMERALAEAKRQASEDALTVINQQEDSSESCWNCGRKASETCSGCNAARYCGSFCQHRDWEKHHHVCGQSLQGPTAVVADPVPGPPEAAHSLGPSLPVGAASPSEAGSAGPSRPGSPSPPGPLDTVPR
-
分子量
93.3 KDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CBFA2T3, also known as Core Binding Factor Alpha 2 and Translocated 3, is a critical transcriptional regulator involved in hematopoiesis and osteogenesis. Its significance has gained attention due to its role as a gene fusion partner in various hematological malignancies, particularly acute myeloid leukemia (AML), where it often forms fusion proteins with other oncogenes. These fusion proteins can disrupt normal gene expression patterns and contribute to leukemogenesis, making CBFA2T3 a focal point of cancer research. Additionally, studies have revealed that CBFA2T3 is involved in the regulation of cell differentiation and development, emphasizing its potential as a therapeutic target. Recent advancements in structural biology, including elucidating the three-dimensional structure of the CBFA2T3 protein, have paved the way for the design of small-molecule inhibitors or modulators that could selectively interfere with its aberrant interactions in cancer. Understanding the functional properties and mechanisms of action of CBFA2T3 and its associated fusion proteins is crucial for developing targeted therapies, improving prognostic markers, and ultimately enhancing treatment options for patients suffering from related malignancies. As a result, ongoing research into CBFA2T3 focuses not only on its biological functions but also on its clinical implications in cancer biology and therapeutic strategies.
